Topcon Announces eyeRISE 2021 Virtual Symposia & Expo
Topcon Healthcare, a leading provider of medical devices and software solutions for the global eye care community, announced today that it will host a two-day virtual symposia and expo entitled eyeRISE on February 9-10, 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210117005025/en/
eyeRISE, or Eye Research Innovation Symposia & Expo, is a new, multi-disciplinary virtual congress showcasing the latest innovations in eye care. It will feature three solutions-focused tracks, delivering clinical and practical education through symposia, roundtable discussions and interactive workshops. (Graphic: Business Wire)
eyeRISE, or Eye Research Innovation Symposia & Expo, is a new, multi-disciplinary virtual congress showcasing the latest innovations in eye care. It will feature three solutions-focused tracks, delivering clinical and practical education through symposia, roundtable discussions and interactive workshops.
The two-day special event will feature more than three dozen globally-renowned speakers representing 17 countries and a range of specialties. Educational tracks are Building Clinical Confidence which includes topics focused on retina, glaucoma and imaging; Entering New Markets which addresses the barriers to entering myopia and dry eye management;and Too Many Patients, Not Enough Time highlighting topics such as ocular telehealth and remote diagnostics.
“We are very excited to announce eyeRISE, a one-of-a-kind, ground-breaking event that will bring together some of the most recognized names in the eye care industry to discuss the latest research and trends in patient care and practice management. In the absence of live meetings, eyeRISE provides an engaging, interactive virtual platform and offers education for a wide range of disciplines. It features solution-focused tracks for real world clinical and business management applications. eyeRISE is the culmination of Topcon’s unwavering commitment to support continued innovation in eye care,” stated Carolyn Evangelista, Global Director of Medical Affairs for Topcon Healthcare.
“eyeRISE will build on the success of our previous ISSOCT conferences and expand to include all facets of eye care, delivering clinical education for the retina, glaucoma and anterior segment subspecialties. The esteemed lecture panel will present their clinical findings on the latest research topics and innovation in eye care. It should prove to be a highly informative and enlightening meeting for all attendees,” stated ISSOCT Chairman Richard F. Spaide, MD, of Vitreous Retina Macula Consultants of New York, United States.
“Having the opportunity to network with colleagues and learn about the latest trends and technologies in eye care is critical for today’s practitioners, particularly in light of the global pandemic. eyeRISE provides practitioners with a unique opportunity to interact with the faculty and each other and gain practical tips and clinical insights. Given the challenges facing today’s eye care practitioners, eyeRISE represents a wonderful learning opportunity for all clinicians,” summarized faculty member Mingguang He, MD, PhD, Professor at the University of Melbourne, Australia.
For more information on eyeRISE or to register for the event, please visit Eyerise2021.com.
About Topcon Healthcare
Topcon Healthcare sees eye health differently. Our vision is to empower providers with smart and efficient technologies for enhanced patient care. Keeping pace with the ever-changing landscape of the healthcare industry, we offer the latest integrated solutions including advanced multi-modal imaging, vendor-neutral data management, safe distancing and ground-breaking remote diagnostic technology.
A globally oriented business, Topcon is focused on developing solutions towards solving societal challenges in the mega-domains of healthcare, agriculture, and infrastructure. In healthcare, these challenges include increasing eye disease, rising medical costs, access to healthcare and physician shortages. By investing in value-driven innovations, Topcon works to enable people to enjoy good health and a high quality of life.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210117005025/en/
Contact information
Christina Kirby
Director, Product Marketing Americas
Topcon Healthcare
E-mail: ckirby@topcon.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists23.4.2024 13:00:00 CEST | Press release
Incyte (Nasdaq:INCY) and Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders, have entered into a definitive agreement under which Incyte has agreed to acquire Escient, including EP262, a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2) and EP547, a first-in-class oral MRGPRX4 antagonist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423725958/en/ “As a company dedicated to innovation and the discovery of transformative medicines, we are excited to add EP262 and EP547 to our portfolio. This acquisition builds on our strategy to develop differentiated and first-in-class medicines with high potential,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “EP262 and EP547 are complementary additions to our portfolio, prov
REPLY S.p.A.: Shareholders’ Meeting Approves the 2023 Financial Statements23.4.2024 12:43:00 CEST | Press release
The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] today approved the Financial Statements for the financial year 2023, confirming the distribution of a gross dividend of €1.00 per share. The dividend will be paid on 22 May 2024, with dividend date set on 20 May 2024 (record date on 21 May 2024). 2023 Financial Statement The Reply Group closed the 2023 financial year with a consolidated turnover of €2,118.0 million, recording a 12.0% increase compared to €1,891.1 million in 2022. Consolidated EBITDA was €325.1 million, up 3.5% compared to €340.3 million recorded in 2022 (growth yoy is 20% net of the release of COVID funds accounted in 2022). EBIT, from January to December, was €292.7 million, up 2.5% compared to €285.5 million recorded in 2022 (growth yoy is 22.7% net of the release of COVID funds accounted in 2022). The Group net profit was at €186.7 million. In 2022, the corresponding figure was €191.0 million. The Shareholders’ Meeting also adopted the following reso
Eaton’s Mobility Group Chosen to Supply Electromechanical Variable Valve Actuation Technology to Great Wall Motor23.4.2024 12:30:00 CEST | Press release
Intelligent power management company Eaton today announced it has been chosen to supply an electromechanical actuation system (EMAS) that can deliver an early intake valve closing (EIVC) to the China-based automaker Great Wall for use in a line of hybrid-electric vehicles (HEV). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423118914/en/ Eaton’s electromechanical actuation system (EMAS) can be easily integrated into a valvetrain and the cylinder head space and controlled by a simple electric actuator. (Photo: Business Wire) “Emissions regulations are driving the adoption of new technologies by our global customers,” said Alessio Lorenzon, global engineering manager, Valves, Eaton’s Mobility Group. “We’re proud to supply Great Wall with our variable valve actuation technology which, in combination with vehicle hybridization, will improve fuel economy in their newest hybrid passenger vehicle lineup.” The Eaton EMAS is a di
Rasa Recognized as a Representative Vendor in Gartner ® Market Guide for Conversational AI Solutions23.4.2024 12:03:00 CEST | Press release
Rasa, a leader in generative conversational AI, proudly announces its recognition as a Representative Vendor in the Gartner® Market Guide for Conversational AI Solutions. Rasa believes this acknowledgment highlights its pivotal role in the future of AI-driven communication and its commitment to delivering innovative solutions that enhance business interactions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240423570629/en/ Rasa has been recognized as a Representative Vendor in the Gartner Market Guide for Conversational AI Solutions, highlighting its role in transforming business operations through AI-driven conversations. This acknowledgment underscores the importance of evaluating the Conversational AI market to enhance customer interactions, achieve cost efficiencies, and elevate customer service. (Graphic: Business Wire) Melissa Gordon, CEO of Rasa, shares her thoughts: “We think recognition from Gartner® validates our
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer23.4.2024 12:00:00 CEST | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use. “Tislelizumab is foundational for BeiGene’s solid tumor portfolio and has demonstrated its potential across multiple tumor types, including NSCLC, in which there remains a significant unmet need at all stages of the disease,” said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeiGene. “Today’s EC authorization marks the second in the region for tislelizumab, with both NSCLC and locally advanced or metastatic esophageal squamous cell carcinoma now approved in the European Union. Second-line use in ESCC was also approved just weeks ago by the U.S. Food and Drug Administration, putting us well on our way to fulfilling our commitment to bring this innovative therapy to many more patients around the